tiprankstipranks
Trending News
More News >
Orpea SA (FR:EMEIS)
:EMEIS
Advertisement

Orpea SA (EMEIS) AI Stock Analysis

Compare
29 Followers

Top Page

FR:EMEIS

Orpea SA

(EMEIS)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 4o)
Rating:48Neutral
Price Target:
€14.00
▲(5.42% Upside)
Orpea SA's overall stock score is primarily impacted by its weak financial performance, characterized by negative profitability and high leverage. While technical indicators show some positive trends, the valuation remains unattractive due to a negative P/E ratio. The earnings call provided some optimism with improvements in revenue and debt reduction, but significant financial challenges persist.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective pricing strategies, enhancing long-term business sustainability.
EBITDA Growth
Improved EBITDA and margins demonstrate operational efficiency, supporting profitability and financial health over the medium term.
Reduced Net Debt
Reduction in net debt enhances financial stability and flexibility, allowing for strategic investments and growth initiatives.
Negative Factors
Negative Net Income
Persistent negative net income indicates ongoing profitability challenges, which can hinder long-term financial sustainability.
High Leverage Ratio
High leverage limits financial flexibility and increases risk, potentially impacting the company's ability to weather economic downturns.
Financial Distress
Negative equity indicates financial instability, posing risks to long-term viability and ability to secure favorable financing.

Orpea SA (EMEIS) vs. iShares MSCI France ETF (EWQ)

Orpea SA Business Overview & Revenue Model

Company DescriptionOrpea SA is a leading European provider of long-term care services, specializing in the management of nursing homes, rehabilitation centers, and assisted living facilities. The company operates across several countries, offering a range of services designed to support elderly individuals and those requiring medical assistance. Orpea's core offerings include residential care, post-acute care, and home care services, focusing on enhancing the quality of life for its residents through comprehensive healthcare and support.
How the Company Makes MoneyOrpea SA primarily generates revenue through the provision of care services in its nursing homes and rehabilitation facilities. Key revenue streams include government reimbursements, private payments from residents, and health insurance reimbursements. The company benefits from partnerships with local governments and health authorities, which provide funding and subsidies for care services. Additionally, Orpea may earn income from ancillary services such as physiotherapy, occupational therapy, and other specialized medical services offered to residents. The company's strategic expansion into new markets and continuous investment in facility enhancements also contribute to its overall earnings.

Orpea SA Earnings Call Summary

Earnings Call Date:Sep 30, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:May 08, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant achievements in revenue growth, occupancy rates, and successful disposals, leading to reduced net debt and positive cash flow. However, challenges remain with negative net income, a high leverage ratio, and difficulties in the Irish market.
Q2-2025 Updates
Positive Updates
Strong Revenue Growth
The company reported an organic revenue growth of 6.2%, driven by a price effect of 3.4% and an occupancy rate effect of 1.8%.
Improved Occupancy Rates
Occupancy rates improved across all regions, nearing 88% on mature perimeters, with nursing homes showing an occupancy rate increase of nearly 200 basis points.
EBITDA Growth
EBITDA grew by 29.5% like-for-like, with a margin increase from 12.1% to 13.8%.
Positive Cash Flow
For the first time in a decade, cash flow turned positive, improving by more than EUR 200 million year-on-year.
Major Disposal Achievements
The company exceeded its disposal target, securing EUR 2.1 billion since mid-2022, which is significantly above the initial target of EUR 1.5 billion.
Reduced Net Debt
Net debt reduced significantly due to successful disposals and real estate transactions, with a pro forma net debt expected to be around EUR 3.8 billion.
Negative Updates
Negative Net Income
Despite improvements, the company still reported a negative net income, although losses have been reduced by EUR 120 million.
High Leverage Ratio
The leverage ratio is still high, at 15.5x at the end of June 2025, though it is improving and expected to fall to almost 13x.
Challenges in Ireland
The company faced challenges in Ireland due to a TV report and political debate, leading to temporary admissions stoppages in some facilities.
Company Guidance
In the recent conference call, MA's management team provided an optimistic outlook for the company's financial performance and strategic initiatives. Key metrics highlighted include a significant improvement in occupancy rates, now nearing 88% on mature perimeters, and a solid organic revenue growth of 6.2% in the first half of 2025. The company reported a 29.5% increase in EBITDA, achieving a like-for-like growth of 79%. Additionally, MA has significantly exceeded its disposal target, securing EUR 2.1 billion since mid-2022, which is expected to materially strengthen its financial structure by reducing net debt and improving the leverage ratio. The management confirmed their midterm outlook, projecting a CAGR of 4% to 5% in revenues and 12% to 16% in EBITDA from 2024 to 2028. They also detailed a new real estate partnership expected to generate EUR 761 million in cash, further enhancing liquidity and financial resilience.

Orpea SA Financial Statement Overview

Summary
Orpea SA's financial performance is concerning due to negative EBIT and net income, indicating operational challenges. The high debt-to-equity ratio and declining stockholder equity highlight financial distress. Despite positive operating cash flow, the company's financial health is undermined by persistent losses and high leverage.
Income Statement
40
Negative
Orpea SA's revenue has shown a steady growth trend with a notable increase from 2020 to 2024. However, profitability metrics are concerning. Both EBIT and Net Income are negative in 2024, indicating operational challenges and lack of profitability. The gross profit margin has improved significantly from previous years, suggesting some operational efficiency gains, but the overall financial health is undermined by persistent losses.
Balance Sheet
30
Negative
The company has a high debt-to-equity ratio due to substantial total debt which has remained high over the years. While the equity ratio is low, indicating high leverage, the company's stockholder equity has been declining, posing a risk to financial stability. Negative stockholders' equity in recent years highlights financial distress.
Cash Flow
50
Neutral
Orpea SA has managed to maintain positive operating cash flow, which is a positive sign of cash-generating capability. The free cash flow has shown growth, but the free cash flow to net income ratio indicates challenges, as net income remains negative. The operating cash flow to net income ratio is strong due to the negative net income, which reflects operational cash flow resilience despite profitability issues.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.64B5.20B4.68B4.30B3.92B
Gross Profit4.51B655.93M713.73M922.68M963.25M
EBITDA731.55M2.80B-3.45B646.07M637.64M
Net Income-412.06M1.35B-4.03B65.19M160.05M
Balance Sheet
Total Assets13.41B13.91B14.49B17.07B16.97B
Cash, Cash Equivalents and Short-Term Investments518.72M692.95M902.99M957.70M894.13M
Total Debt8.86B9.16B13.38B12.25B10.77B
Total Liabilities11.69B12.02B16.00B14.74B13.48B
Stockholders Equity1.72B1.89B-1.50B2.32B3.50B
Cash Flow
Free Cash Flow328.61M216.90M244.74M331.85M283.29M
Operating Cash Flow472.05M366.14M409.73M753.75M777.73M
Investing Cash Flow-140.43M-318.17M-657.49M-1.41B-1.01B
Financing Cash Flow-458.08M-259.44M151.81M718.30M285.80M

Orpea SA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price13.28
Price Trends
50DMA
13.94
Negative
100DMA
13.15
Positive
200DMA
12.02
Positive
Market Momentum
MACD
-0.18
Negative
RSI
47.71
Neutral
STOCH
68.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EMEIS, the sentiment is Positive. The current price of 13.28 is below the 20-day moving average (MA) of 13.38, below the 50-day MA of 13.94, and above the 200-day MA of 12.02, indicating a neutral trend. The MACD of -0.18 indicates Negative momentum. The RSI at 47.71 is Neutral, neither overbought nor oversold. The STOCH value of 68.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:EMEIS.

Orpea SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
€256.34M12.136.64%2.78%13.31%-13.07%
58
Neutral
€1.25B-27.06-1.70%1.98%85.87%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
€2.20B-7.50-16.66%6.30%-100.37%
48
Neutral
€999.88M-4.36%4.70%-0.37%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:EMEIS
Orpea SA
13.28
7.68
137.23%
FR:CLARI
Clariane
3.76
1.83
95.02%
FR:LNA
LNA Sante SA
23.40
1.22
5.49%
FR:GDS
Ramsay Generale de Sante
9.00
-2.60
-22.41%

Orpea SA Corporate Events

Orpea SA Earnings Call: Growth Amidst Challenges
Oct 10, 2025

The recent earnings call for Orpea SA painted a mixed picture of the company’s financial health, with notable achievements in revenue growth and occupancy rates, alongside challenges such as negative net income and a high leverage ratio. The call highlighted the company’s strategic efforts to reduce net debt and improve cash flow, despite facing difficulties in the Irish market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 11, 2025